Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Why some dogs do not respond to epilepsy treatments
border collie
Past research has shown around a third of dogs do not respond to anti-epilepsy drugs.
Breed and sex impact the effectiveness of AEDs, says RVC

New research has shed light on why around a third of dogs do not respond to epilepsy treatments.

Sex, breed and frequency of seizures all affect the likelihood of achieving remission, according to specialists from the Royal Veterinary College (RVC).

Epilepsy affects around 50,000 dogs and 600,000 people in the UK, making it the most common chronic neurological condition found in both dogs and humans. Research has shown anti-epilepsy drugs (AEDs) fail to reduce seizures by 50 per cent in a third of cases.

RVC researchers sought to find out why, using patient data from six years of medical history, taken from the college's small animal referral hospital.

Just 14 per cent of the dogs studied were in seizure-free remission at the point of follow up.

The findings, which will be published in the academic journal PLOS ONE, show that male dogs were less likely than female dogs to become seizure-free while receiving AED treatment.

Border collies and German shepherds were also found to be significantly less likely to respond to treatment. Past studies have looked at the impact of AEDs on different dog types, but the RVC was able to explore how this affects a wider variety of breeds.

Researchers say they also discovered that the likelihood of achieving remission is not affected by the number of seizures experienced before treatment begins. Traditionally in human medicine, treatment is given immediately after the onset of epilepsy.

Rowena Packer, co-author of the study and clinical investigations research assistant at the RVC, said managing owners' expectations of drug treatments for epilepsy is important.

"In its worst form canine epilepsy can be life threatening to dogs, but it is a dog's long-term quality of life that is most affected. It can also take a toll on the owners who have to manage this unpredictable, uncontrollable condition."

Lead author Professor Holger Volk, specialist in neurology and neurosurgery and clinical director of the RVC's small animal referral clinic, added: "Drug treatments can be successful in reducing seizures, but it is important to note that consistent remission is difficult to attain."

Researchers say further study of AED treatment in dogs could even improve understanding of epilepsy in humans.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.